<DOC>
	<DOCNO>NCT01685801</DOCNO>
	<brief_summary>This study multiple within participant crossover study evaluate effect ivacaftor lung function participant age 12 year older cystic fibrosis ( CF ) phenotypic molecular evidence residual CF transmembrane conductance regulator ( CFTR ) function .</brief_summary>
	<brief_title>Pilot Study Testing Effect Ivacaftor Lung Function Subjects With Cystic Fibrosis Residual CFTR Function</brief_title>
	<detailed_description>CFTR Mutations associate residual function defective messenger ribonucleic acid ( mRNA ) splice include follow : R117H , E56K , P67L , D110E , D110H , R117C , R347H , R352Q , A455E , D579G , S945L , L206W , R1070W , F1074L , D1152H , S1235R , D1270N , 2789+5G- &gt; A , 3849+10kbC- &gt; T , 3272-26A- &gt; G , 711+5G- &gt; A , 3120G- &gt; A , 1811+1.6kbA- &gt; G , 711+3A- &gt; G , 1898+3A- &gt; G , 1898+1G- &gt; A , 1717-1G- &gt; A , 1717-8G- &gt; A , 1342-2A- &gt; C , 405+3A- &gt; C , 1716G/A 1811+1G- &gt; C , 1898+5G- &gt; T , 3850-3T- &gt; G , IVS14b+5G- &gt; A , 1898+1G- &gt; T , 4005+2T- &gt; C , 621+3A- &gt; G , 621+1G- &gt; T .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Male female participant confirm diagnosis CF Clinical evidence residual CFTR function base 1 follow : 1 ) Clinically document residual exocrine pancreatic function , 2 ) Sweat chloride value less equal ( &lt; = ) 80 millimole per liter ( mmol/L ) screening , 3 ) Age diagnosis great equal ( &gt; = ) 12 year least 1 copy CFTR mutation associate residual CFTR function defective mRNA splice FEV1 &gt; = 40 percent ( % ) 12 year age old Willing agree meet contraception requirement Able swallow tablet A copy follow CFTR mutation : G551D , G178R , S549N , S549R , G551S , G970R , G1244E , S1251N , S1255P , G1349D Unable perform spirometry An acute upper low respiratory infection , pulmonary exacerbation , change therapy ( include antibiotic ) pulmonary disease within 4 week Day 1 Ongoing participation another therapeutic clinical study prior participation investigational drug study within 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>